Australia markets close in 4 hours 52 minutes
  • ALL ORDS

    7,579.10
    +50.10 (+0.67%)
     
  • ASX 200

    7,289.50
    +44.40 (+0.61%)
     
  • AUD/USD

    0.7041
    -0.0016 (-0.22%)
     
  • OIL

    69.74
    +0.25 (+0.36%)
     
  • GOLD

    1,781.80
    +2.30 (+0.13%)
     
  • BTC-AUD

    71,673.03
    +1,913.13 (+2.74%)
     
  • CMC Crypto 200

    1,286.62
    +26.46 (+2.10%)
     
  • AUD/EUR

    0.6238
    -0.0007 (-0.12%)
     
  • AUD/NZD

    1.0450
    +0.0013 (+0.13%)
     
  • NZX 50

    12,651.30
    +53.49 (+0.42%)
     
  • NASDAQ

    15,846.16
    +134.12 (+0.85%)
     
  • FTSE

    7,232.28
    +109.96 (+1.54%)
     
  • Dow Jones

    35,227.03
    +646.95 (+1.87%)
     
  • DAX

    15,380.79
    +210.81 (+1.39%)
     
  • Hang Seng

    23,349.38
    -417.31 (-1.76%)
     
  • NIKKEI 225

    27,927.37
    0.00 (0.00%)
     

SPPI, LDI & LGVN Upcoming Class Action Deadlines - Bronstein, Gewirtz & Grossman, LLC

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Class Period: December 27, 2018 - August 5, 2021
Deadline: November 1, 2021
For more info: www.bgandg.com/sppi.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facility of ROLONTIS (eflapegrastim), a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application (the "ROLONTIS BLA") in its current form; (3) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

loanDepot, Inc. (NYSE: LDI)
Class Period: on behalf of shareholders who purchased or otherwise acquired loanDepot securities pursuant and/or traceable to loanDepot’s February 16, 2021, initial public offering (the "IPO" or the "Offering")
Deadline: November 8, 2021
For more info: www.bgandg.com/ldi.
The Complaint alleges that the Registration Statement was negligently prepared and omitted to disclose material adverse facts. Specifically, Defendants failed to disclose to investors that: (1) the Company's refinance originations had already declined substantially at the time of the IPO due to industry over-capacity and increased competition; (2) the Company's gain-on-sale margins had already declined substantially at the time of the IPO; (3) as a result, the Company's revenue and growth would be negatively impacted; and (4) consequently, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Longeveron Inc. (NASDQ: LGVN)
Class Period: on behalf of shareholders who purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (b) Longeveron securities between February 12, 2021 and August 12, 2021, inclusive (the “Class Period”)
Deadline: November 12, 2021
For more info: www.bgandg.com/lgvn.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facility of ROLONTIS (eflapegrastim), a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application (the "ROLONTIS BLA") in its current form; (3) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting